Teva Interest Expense from 2010 to 2024

TEVA Stock  USD 22.09  0.78  3.66%   
Teva Pharma's Interest Expense is increasing over the years with slightly volatile fluctuation. Overall, Interest Expense is expected to go to about 1.1 B this year. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
First Reported
1998-03-31
Previous Quarter
241 M
Current Value
272 M
Quarterly Volatility
275.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 1.1 B or Total Revenue of 9.5 B, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0042 or PTB Ratio of 1.48. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
  
Check out the analysis of Teva Pharma Correlation against competitors.

Latest Teva Pharma's Interest Expense Growth Pattern

Below is the plot of the Interest Expense of Teva Pharma Industries over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Teva Pharma's Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
Interest Expense10 Years Trend
Slightly volatile
   Interest Expense   
       Timeline  

Teva Interest Expense Regression Statistics

Arithmetic Mean755,210,000
Geometric Mean508,845,268
Coefficient Of Variation52.76
Mean Deviation340,046,667
Median959,000,000
Standard Deviation398,469,978
Sample Variance158778.3T
Range1.3B
R-Value0.79
Mean Square Error64447T
R-Squared0.62
Significance0.0005
Slope70,333,036
Total Sum of Squares2222896.5T

Teva Interest Expense History

20241.1 B
2023B
2022966 M
20211.1 B
2020963 M
2019822 M
2018959 M

About Teva Pharma Financial Statements

Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Interest Expense, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest ExpenseB1.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out the analysis of Teva Pharma Correlation against competitors.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.85)
Revenue Per Share
14.879
Quarterly Revenue Growth
0.125
Return On Assets
0.0556
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.